Michal Hensler
Overview
Explore the profile of Michal Hensler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buque A, Bloy N, Petroni G, Jimenez-Cortegana C, Sato A, Iribarren C, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39661487
Background: Hormone receptor (HR)+ breast cancer is poorly responsive to immune checkpoint inhibitors (ICIs). In some settings, radiation therapy (RT) has been shown to mediate immunostimulatory effects and promote ICI...
2.
Lanickova T, Hensler M, Kasikova L, Vosahlikova S, Angelidou A, Pasulka J, et al.
Clin Cancer Res
. 2024 Aug;
31(1):164-180.
PMID: 39163092
Purpose: Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus, conventional chemotherapeutics...
3.
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, et al.
Nat Commun
. 2024 Mar;
15(1):2528.
PMID: 38514660
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate...
4.
Pavelkova L, Taborska E, Syding L, Plackova K, Simonova E, Hladikova K, et al.
Transl Oncol
. 2024 Jan;
41:101884.
PMID: 38242007
The profile of the antitumor immune response is an important factor determining patient clinical outcome. However, the influence of the tissue contexture on the composition of the tumor microenvironments of...
5.
Holicek P, Truxova I, Rakova J, Salek C, Hensler M, Kovar M, et al.
Cell Death Dis
. 2023 Mar;
14(3):209.
PMID: 36964168
While type I interferon (IFN) is best known for its key role against viral infection, accumulating preclinical and clinical data indicate that robust type I IFN production in the tumor...
6.
Hensler M, Rakova J, Kasikova L, Lanickova T, Pasulka J, Holicek P, et al.
Oncoimmunology
. 2022 Jul;
11(1):2101596.
PMID: 35898703
Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, the clinical efficacy of DC-based vaccines remains suboptimal, largely reflecting local and...
7.
Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, et al.
Clin Cancer Res
. 2022 May;
28(14):3053-3065.
PMID: 35536547
Purpose: The successful implementation of immune checkpoint inhibitors (ICI) in the clinical management of various solid tumors has raised considerable expectations for patients with epithelial ovarian carcinoma (EOC). However, EOC...
8.
Yamazaki T, Wennerberg E, Hensler M, Buque A, Kraynak J, Fucikova J, et al.
Oncoimmunology
. 2021 Aug;
10(1):1962592.
PMID: 34408925
LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only...
9.
Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, et al.
Oncoimmunology
. 2021 Mar;
10(1):1889822.
PMID: 33758676
Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8 cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death...
10.
Bardova K, Funda J, Pohl R, cajka T, Hensler M, Kuda O, et al.
Nutrients
. 2020 Dec;
12(12).
PMID: 33291653
Long-chain n-3 polyunsaturated fatty acids (Omega-3) and anti-diabetic drugs thiazolidinediones (TZDs) exhibit additive effects in counteraction of dietary obesity and associated metabolic dysfunctions in mice. The underlying mechanisms need to...